Výsledky vyhledávání - "van Riel, Piet LCM"

Akademický článek

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Autor: van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A

Publikováno v: BMC Musculoskeletal Disorders, Vol 13, Iss 1, p 184 (2012)

Abstract Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Met

Externí odkaz: https://doaj.org/article/949de4259e544872b24ec1a9d87f351c

Zobrazit plný text záznamu

Akademický článek

Are patients' judgments of health status really different from the general population?

Autor: Ruers Theo JM, Tromp Noor, Krabbe Paul FM, van Riel Piet LCM

Publikováno v: Health and Quality of Life Outcomes, Vol 9, Iss 1, p 31 (2011)

Abstract Background Many studies have found discrepancies in valuations for health states between the general population (healthy people) and people who actually experience illness (patients). Such differences may be explained by referring to various

Externí odkaz: https://doaj.org/article/bc533fbfda104c62bdf2e38ba1c9782b

Zobrazit plný text záznamu

Akademický článek

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Autor: van Riel Piet LCM, Hekster Yechiel A, Wolbink GJ, den Broeder Alfons A, van den Bemt Bart JF, Benraad Bart, van den Hoogen Frank HJ

Publikováno v: BMC Musculoskeletal Disorders, Vol 12, Iss 1, p 12 (2011)

Abstract Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough

Externí odkaz: https://doaj.org/article/9fb892295ada46489f446baf63bfcd88

Zobrazit plný text záznamu

Akademický článek

Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data

Autor: Beretta Lorenzo, Santaniello Alessandro, van Riel Piet LCM, Coenen Marieke JH, Scorza Raffaella

Publikováno v: BMC Bioinformatics, Vol 11, Iss 1, p 416 (2010)

Abstract Background Epistasis is recognized as a fundamental part of the genetic architecture of individuals. Several computational approaches have been developed to model gene-gene interactions in case-control studies, however, none of them is suita

Externí odkaz: https://doaj.org/article/1223753b355d40b09e0252f82c3914fe

Zobrazit plný text záznamu

Akademický článek

Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, Toll-like receptors and rheumatoid synovial fluid

Autor: Schreurs B Willem, Roelofs Mieke F, le Blanc Linda MP, van der Voort Robbert, van Lieshout Antoine WT, van Riel Piet LCM, Adema Gosse J, Radstake Timothy RDJ

Publikováno v: BMC Immunology, Vol 7, Iss 1, p 23 (2006)

Abstract Background The T cell attracting chemokine CCL18 is produced by antigen presenting cells and a role for CCL18 has been suggested in the pathogenesis of a variety of diseases. Rheumatoid arthritis (RA) is one of these conditions, in which abu

Externí odkaz: https://doaj.org/article/8458179723084b34b9f695f2a9a70002

Zobrazit plný text záznamu

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Autor: Flendrie, Marcel, Vissers, Wynand HPM, Creemers, Marjonne CW, de Jong, Elke MGJ, van de Kerkhof, Peter CM, van Riel, Piet LCM

Publikováno v: Arthritis Research & Therapy

Various dermatological conditions have been reported during tumor necrosis factor (TNF)-alpha-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up to investigate the number and nature o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::85fe2886b238fb09779c7339e809136c
http://europepmc.org/articles/PMC1174960

Zobrazit plný text záznamu

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis

Autor: van Riel, Piet LCM, Fransen, Jaap

Publikováno v: Arthritis Research & Therapy

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ae9a7fe6a5b13f3e08c72532885c2d75
https://pubmed.ncbi.nlm.nih.gov/16207323

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání